Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin

References

• Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30:1042 - 9; http://dx.doi.org/10.1200/JCO.2010.30.3404; PMID: 22370326
   PubMed Web of Science ®Google Scholar
• Bruynzeel AM, Abou El Hassan MA, Schalkwijk C, Berkhof J, Bast A, Niessen HW, et al. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 2007; 96:937 - 43; http://dx.doi.org/10.1038/sj.bjc.6603640; PMID: 17325706
   PubMed Web of Science ®Google Scholar
• Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994; 105:897 - 904; http://dx.doi.org/10.1378/chest.105.3.897; PMID: 8131560
   PubMed Web of Science ®Google Scholar
• Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72:561 - 6; http://dx.doi.org/10.1136/hrt.72.6.561; PMID: 7857740
   PubMedGoogle Scholar
• Zhu J, Zhang J, Zhang L, Du R, Xiang D, Wu M, et al. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed Pharmacother 2011; 65:481 - 5; http://dx.doi.org/10.1016/j.biopha.2011.06.005; PMID: 22000485
   PubMed Web of Science ®Google Scholar
• Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011; 11:1008 - 16; http://dx.doi.org/10.4161/cbt.11.12.15540; PMID: 21464611
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, Wu M, et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 2010; 643:247 - 53; http://dx.doi.org/10.1016/j.ejphar.2010.06.024; PMID: 20599921
   PubMed Web of Science ®Google Scholar
• Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007; 21:413 - 27; http://dx.doi.org/10.1016/j.bbi.2006.11.004; PMID: 17178209
   PubMed Web of Science ®Google Scholar
• Baldassare JJ, Bi Y, Bellone CJ. The role of p38 mitogen-activated protein kinase in IL-1 beta transcription. J Immunol 1999; 162:5367 - 73; PMID: 10228013
   PubMed Web of Science ®Google Scholar
• Kent LM, Smyth LJ, Plumb J, Clayton CL, Fox SM, Ray DW, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N’-(2-[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]aminoethyl)guanidine (SB706504). J Pharmacol Exp Ther 2009; 328:458 - 68; http://dx.doi.org/10.1124/jpet.108.142950; PMID: 19004925
   PubMed Web of Science ®Google Scholar
• Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 2000; 28:Suppl N67 - 77; http://dx.doi.org/10.1097/00003246-200004001-00008; PMID: 10807318
   PubMed Web of Science ®Google Scholar
• Elsea CR, Roberts DA, Druker BJ, Wood LJ. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One 2008; 3:e2355; http://dx.doi.org/10.1371/journal.pone.0002355; PMID: 18523641
   PubMed Web of Science ®Google Scholar
• Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754:253 - 62; http://dx.doi.org/10.1016/j.bbapap.2005.08.017; PMID: 16198162
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9:537 - 49; http://dx.doi.org/10.1038/nrc2694; PMID: 19629069
   PubMed Web of Science ®Google Scholar
• Avdi NJ, Malcolm KC, Nick JA, Worthen GS. A role for protein phosphatase-2A in p38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH(2)-terminal kinase pathway in human neutrophils. J Biol Chem 2002; 277:40687 - 96; http://dx.doi.org/10.1074/jbc.M204455200; PMID: 12186863
   PubMed Web of Science ®Google Scholar
• Lahti A, Sareila O, Kankaanranta H, Moilanen E. Inhibition of p38 mitogen-activated protein kinase enhances c-Jun N-terminal kinase activity: implication in inducible nitric oxide synthase expression. BMC Pharmacol 2006; 6:5; http://dx.doi.org/10.1186/1471-2210-6-5; PMID: 16504051
   PubMedGoogle Scholar
• Sauter KA, Magun EA, Iordanov MS, Magun BE. ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. Cancer Biol Ther 2010; 10:258 - 66; http://dx.doi.org/10.4161/cbt.10.3.12367; PMID: 20559024
   PubMedGoogle Scholar
• Bloem LJ, Pickard TR, Acton S, Donoghue M, Beavis RC, Knierman MD, et al. Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase. J Mol Cell Cardiol 2001; 33:1739 - 50; http://dx.doi.org/10.1006/jmcc.2001.1437; PMID: 11549352
   PubMed Web of Science ®Google Scholar
• Gotoh I, Adachi M, Nishida E. Identification and characterization of a novel MAP kinase kinase kinase, MLTK. J Biol Chem 2001; 276:4276 - 86; http://dx.doi.org/10.1074/jbc.M008595200; PMID: 11042189
   PubMed Web of Science ®Google Scholar
• Gross EA, Callow MG, Waldbaum L, Thomas S, Ruggieri R. MRK, a mixed lineage kinase-related molecule that plays a role in gamma-radiation-induced cell cycle arrest. J Biol Chem 2002; 277:13873 - 82; http://dx.doi.org/10.1074/jbc.M111994200; PMID: 11836244
   PubMed Web of Science ®Google Scholar
• Liu TC, Huang CJ, Chu YC, Wei CC, Chou CC, Chou MY, et al. Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif. Biochem Biophys Res Commun 2000; 274:811 - 6; http://dx.doi.org/10.1006/bbrc.2000.3236; PMID: 10924358
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127 - 32; http://dx.doi.org/10.1038/nbt1358; PMID: 18183025
   PubMed Web of Science ®Google Scholar
• Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804:445 - 53; http://dx.doi.org/10.1016/j.bbapap.2009.11.008; PMID: 19922818
   PubMed Web of Science ®Google Scholar
• Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:1046 - 51; http://dx.doi.org/10.1038/nbt.1990; PMID: 22037378
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765 - 9; http://dx.doi.org/10.1038/sj.bjc.6603170; PMID: 16721371
   PubMed Web of Science ®Google Scholar
• Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol 2011; 38:Suppl 1 S3 - 9; http://dx.doi.org/10.1053/j.seminoncol.2011.01.016; PMID: 21419934
   PubMedGoogle Scholar
• Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 2012; 19:938 - 44; http://dx.doi.org/10.2174/092986712799320736; PMID: 22214462
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16:401 - 12; http://dx.doi.org/10.1016/j.ccr.2009.09.028; PMID: 19878872
   PubMed Web of Science ®Google Scholar
• Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 1981; 5:267 - 70; http://dx.doi.org/10.1007/BF00434396; PMID: 7261254
   PubMed Web of Science ®Google Scholar
• Korcheva V, Wong J, Corless C, Iordanov M, Magun B. Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome. Am J Pathol 2005; 166:323 - 39; http://dx.doi.org/10.1016/S0002-9440(10)62256-0; PMID: 15632024
   PubMed Web of Science ®Google Scholar
• Vrignaud P, Eghbali H, Hoerni B, Iliadis A, Robert J. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin’s patients. Eur J Cancer Clin Oncol 1985; 21:1307 - 13; http://dx.doi.org/10.1016/0277-5379(85)90309-8; PMID: 3865777
   PubMedGoogle Scholar
• Mross K, Maessen P, van der Vijgh WJ, Gall H, Boven E, Pinedo HM. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6:517 - 26; PMID: 3162516
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002; 234-235:119 - 24; http://dx.doi.org/10.1023/A:1015976430790; PMID: 12162424
   PubMed Web of Science ®Google Scholar
• Hassan F, Islam S, Mu MM, Ito H, Koide N, Mori I, et al. Lipopolysaccharide prevents doxorubicin-induced apoptosis in RAW 264.7 macrophage cells by inhibiting p53 activation. Mol Cancer Res 2005; 3:373 - 9; http://dx.doi.org/10.1158/1541-7786.MCR-05-0046; PMID: 16046548
   PubMed Web of Science ®Google Scholar
• Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69:695 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-3076; PMID: 19147586
   PubMed Web of Science ®Google Scholar
• Riad A, Bien S, Gratz M, Escher F, Westermann D, Heimesaat MM, et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail 2008; 10:233 - 43; http://dx.doi.org/10.1016/j.ejheart.2008.01.004; PMID: 18321777
   PubMed Web of Science ®Google Scholar
• Korcheva V, Wong J, Lindauer M, Jacoby DB, Iordanov MS, Magun B. Role of apoptotic signaling pathways in regulation of inflammatory responses to ricin in primary murine macrophages. Mol Immunol 2007; 44:2761 - 71; http://dx.doi.org/10.1016/j.molimm.2006.10.025; PMID: 17257680
   PubMed Web of Science ®Google Scholar
• Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Chen SL, et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol 1997; 17:3373 - 81; PMID: 9154836
   PubMed Web of Science ®Google Scholar
• Jandhyala DM, Ahluwalia A, Obrig T, Thorpe CM. ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol 2008; 10:1468 - 77; http://dx.doi.org/10.1111/j.1462-5822.2008.01139.x; PMID: 18331592
   PubMed Web of Science ®Google Scholar
• Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, et al. Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 2005; 280:19298 - 305; http://dx.doi.org/10.1074/jbc.M413059200; PMID: 15737997
   PubMed Web of Science ®Google Scholar
• Villar VH, Vögler O, Martínez-Serra J, Ramos R, Calabuig-Fariñas S, Gutiérrez A, et al. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 2012; 7:e37735; http://dx.doi.org/10.1371/journal.pone.0037735; PMID: 22662203
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Saltz LB. Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. Gastroenterology 2011; 141:e19 - 20, author reply e20-1; http://dx.doi.org/10.1053/j.gastro.2011.04.063; PMID: 21794834
   PubMedGoogle Scholar